Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04671017
Recruitment Status : Recruiting
First Posted : December 17, 2020
Last Update Posted : December 30, 2020
Sponsor:
Collaborator:
National Institute for Health Research, United Kingdom
Information provided by (Responsible Party):
Valneva Austria GmbH

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A multicenter, 3-arm randomized dose finding study in UK to evaluate safety, tolerability and immunogenicity of a vaccine candidate against Covid-19. 150 healthy volunteers will be enrolled and receive two shots of the vaccine candidate.

Condition or disease Intervention/treatment Phase
Sars-Cov-2 Virus Infection Biological: VLA2001 Phase 1 Phase 2

Detailed Description:

The multicenter, dose finding Phase 1/2 study starts off with an open-label, dose-escalation part, thereafter, during the double-blind part of study, participants will be randomized 1:1:1 to receive the low, medium or high dose of the vaccine (VLA2001). All participants will received a total of two vaccinations intramuscularly, on day 1 and day 22.

The first 5 participants in each dose group will receive VLA2001 open label, starting with the low dose of VLA2001. If no safety concerns are identified, the next 5 subjects will receive the medium dose of the vaccine. Again, if no safety issues are identified, 5 participants will be vaccinated with the high dose vaccine. A Data Safety and Monitoring Board (DSMB) will review accrued safety data before randomization of the remaining 135 subjects across all sites will be initiated.

All study participants will be followed up for safety and immunogenicity up to approximately 6 months after receiving their second vaccination.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:
  1. st phase Sequential (open-label randomized phase)
  2. nd phase Parallel Assignment (double-blinded randomized phase )
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
  1. st phase is open-label randomized
  2. nd phase is double-blind randomized (Participant, Investigator )
Primary Purpose: Prevention
Official Title: A Phase I/II Randomized, Two Parts, Dose-Finding Study To Evaluate The Safety, Tolerability and Immunogenicity Of An Inactivated, Adjuvanted Sars-Cov-2 Virus Vaccine Candidate (VLA2001), Against Covid-19 In Healthy Subjects
Actual Study Start Date : December 16, 2020
Estimated Primary Completion Date : February 15, 2021
Estimated Study Completion Date : August 2021
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Low Dose: VLA2001 Biological: VLA2001
whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phosphor-guanine (CpG) 1018 in combination with aluminium hydroxide
Experimental: Medium Dose: VLA2001 Biological: VLA2001
whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phosphor-guanine (CpG) 1018 in combination with aluminium hydroxide
Experimental: High Dose: VLA2001 Biological: VLA2001
whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phosphor-guanine (CpG) 1018 in combination with aluminium hydroxide


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Frequency and severity of solicited AEs (local and systemic reactions) within 7 days after any vaccination [ Time Frame: until Day 29 ]
  2. Geometric mean titre (GMT) for neutralizing antibodies against SARS-CoV-2 [ Time Frame: Day 36 ]

Secondary Outcome Measures :
  1. Frequency and severity of any unsolicited AE [ Time Frame: until Day 36 ]
  2. Frequency and severity of any vaccine-related AE [ Time Frame: until Day 36 ]
  3. Frequency and severity of any AE [ Time Frame: until Day 208 ]
  4. Frequency and severity of any vaccine-related AE [ Time Frame: until Day 208 ]
  5. Frequency and severity of any SAE [ Time Frame: until Day 36 ]
  6. Frequency and severity of any AESI [ Time Frame: until Day 36 ]
  7. Frequency and severity of any SAE [ Time Frame: until Day 208 ]
  8. Frequency and severity of an AESI [ Time Frame: until Day 208 ]
  9. Immune response as measured by neutralizing antibody titres against SARS-CoV-2 [ Time Frame: until Day 208 ]
  10. Proportion of subjects with seroconversion in terms of neutralizing antibodies [ Time Frame: until Day 208 ]
  11. Fold increase of SARS-CoV-2 neutralizing antibody titres compared with baseline [ Time Frame: until Day 208 ]
  12. GMTs for IgG antibodies against SARS-CoV-2 [ Time Frame: until Day 208 ]
  13. Proportion of subjects with seroconversion in terms of IgG antibodies against SARS-CoV-2 in subjects negative for SARS-CoV-2 at screening [ Time Frame: until Day 208 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria - Subjects who meet ALL of the following criteria are eligible for the study:

  1. Subject is 18 to 55 years of age
  2. Subject who has a smart phone and is willing and able to install and use the eDiary.
  3. Subject has an understanding of the study and its procedures, agrees to its provisions, and voluntarily gives written informed consent prior to any study-related procedures.
  4. Subject is generally healthy as determined by the Investigator
  5. Subject has a Body Mass Index (BMI) of 18.0-30.0 kg/m2

  6. If subject is of childbearing potential:

    1. Subject has practiced an adequate method of contraception during the 30 days before screening (Visit 0).
    2. Subject has a negative serum or urine pregnancy test at screening (Visit 0) or Visit 1, respectively.
    3. Subject agrees to employ adequate birth control measures up to Day 106 (Visit 5).

Exclusion criteria - Subjects who meet ANY of the following criteria are NOT eligible for this study:

  1. Clinically significant infection or other acute illness, including fever ≥ 38°C within 24 hours prior to the planned study vaccination.
  2. History of laboratory-confirmed SARS-CoV-2 infection.
  3. Subject had close contact to persons with confirmed SARS-CoV-2 infection within 30 days prior to screening (Visit 0).
  4. Subject has participated in a clinical study involving an investigational SARS-CoV-2 vaccine.
  5. Subject has an acute or recent infection not due to SARS-CoV-2
  6. Subject has a history of SARS-CoV-1 or MERS infection (self-reported)
  7. Subject tests positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
  8. Subject has received any vaccine within 30 days prior Visit 1 other than the study intervention, with the exception of the seasonal influenza vaccination.
  9. Subject has abnormal findings in any required study investigations (including medical history, physical examination, and clinical laboratory) considered clinically relevant by the Investigator.
  10. Subjects with either medical history of or present acute or progressive, unstable or uncontrolled clinical conditions that pose a risk for participation or completion of the study, based on Investigator's clinical judgement.
  11. Subjects with underlying diseases with a high risk of developing severe COVID-19 symptoms if infected
  12. Subject has a history of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. If there has been surgical excision or treatment more than 5 years ago that is considered to have achieved a cure, the subject may be enrolled. A history of hematologic malignancy is a permanent exclusion. Subjects with a history of skin cancer must not be vaccinated at the previous tumour site.
  13. Subject has a known or suspected defect of the immune system, such as subjects with congenital or acquired immune deficiency
  14. Subject received immuno-suppressive therapy within 4 weeks prior to Visit 1 or receipt of immunosuppressive therapy is expected during the study.
  15. Subject has a history of any vaccine related contraindicating event
  16. Subject presents with clinical conditions representing a contraindication to intramuscular vaccination and blood draws.
  17. Subject is pregnant, has plans to become pregnant up to Day 106 of the study or lactating at the time of enrolment.
  18. Subject has donated blood, blood fractions or plasma within 4 weeks prior to Visit 1 or received blood-derived products (e.g. plasma) within 12 weeks prior to Visit 1 in this study or plans to donate blood or use blood products during the study.
  19. Subject with clinically significant bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder) or prior history of significant bleeding or bruising following IM injections or venepuncture.
  20. Subject has a rash, dermatological condition or tattoos that would, in the opinion of the Investigator, interfere with injection site reaction rating.
  21. Subject has a known or suspected problem with alcohol or drug abuse as determined by the Investigator.
  22. Subject has any condition that, in the opinion of the Investigator, may compromise the subject's well-being, might interfere with evaluation of study endpoints, or would limit the subject's ability to complete the study.
  23. Subject is committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities).
  24. Subject has participated in another clinical study involving an investigational medicinal product (IMP) or device within 4 weeks prior to Visit 0 (screening) or is scheduled to participate in another clinical study involving an IMP, or device during the course of this study.
  25. Subject is a member of the team conducting the study or in a dependent relationship with one of the study team members.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04671017


Contacts
Layout table for location contacts
Contact: Valneva Clinical Development +43 1 206 20 ext 0 office@valneva.com

Locations
Layout table for location information
United Kingdom
Queen Elizabeth Hospital Not yet recruiting
Birmingham, United Kingdom, B15 2TH
Contact: Chris Green, Dr.         
University Hospital Bristol and Weston NHS Foundation Trust Recruiting
Bristol, United Kingdom, BS1 3NU
Contact: Rajeka Lazarus, Dr.         
Newcastle University Medical School Not yet recruiting
Newcastle, United Kingdom, NE7 7DN
Contact: Christopher Duncan, Dr.         
Southampton NIHR Clinical Research Facility Not yet recruiting
Southampton, United Kingdom, SO16 6YD
Contact: Saul Faust, Prof.         
Sponsors and Collaborators
Valneva Austria GmbH
National Institute for Health Research, United Kingdom
Investigators
Layout table for investigator information
Study Chair: Valneva Clinical Development Valneva Austria GmbH
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Valneva Austria GmbH
ClinicalTrials.gov Identifier: NCT04671017    
Other Study ID Numbers: VLA2001-201
First Posted: December 17, 2020    Key Record Dates
Last Update Posted: December 30, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Valneva Austria GmbH:
VLA2001
Sars-Cov-2 Virus Infection
Covid-19
inactivated-adjuvanted Sars-Cov-2 virus vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Virus Diseases